Key result
Recombinant factor IX achieves hemostasis in ~94% of hemorrhages in untreated hemophilia B.
Answers are grounded in this paper and cite their sources.
This international clinical trial evaluated the safety and efficacy of recombinant factor IX (rFIX) in previously untreated patients (PUPs) with severe or moderately severe hemophilia B (FIX activity, < or = 3 IU/dL). Sixty-three PUPs aged younger than 1 month to 14 years received rFIX (median treatment duration, 37 months; range, 4-64 months). Mean rFIX recovery (0.68 +/- 0.27 IU/dL per IU/kg) remained constant over 5 years and was similar in infants (1 month to < 2 years) and children (2 to < 12 years). Fifty-four PUPs used rFIX (median dose, 62.7 IU/kg per infusion; range, 8.2-292 IU/kg) to treat 997 hemorrhages. Bleeding was well controlled, with 75% of hemorrhages requiring only one rFIX infusion. Response to rFIX was "excellent" or "good" in 94% of cases. Effective hemostasis was achieved in 32 PUPs receiving rFIX for routine prophylaxis, with 91% of prophylaxis responses rated "excellent." rFIX administered for 30 surgical procedures in 23 PUPs achieved hemostasis for all rated procedures. Five patients experienced allergic-type manifestations, including 2 (3%) patients who developed FIX inhibitors (both > 5 BU/dL). rFIX was well tolerated, with no associated thrombotic events or evidence of viral transmission. These data indicate that rFIX is a safe and effective treatment for PUPs with hemophilia B.
No takes yet. Share an insight, caveat, or question.
Amy D. Shapiro (2004) studied Severe or moderately severe hemophilia B (n=63). Recombinant factor IX (rFIX) was evaluated on Excellent or good hemostatic response to hemorrhage treatment. Recombinant factor IX achieved excellent or good hemostasis in 94% of hemorrhages and 3% FIX inhibitor rate in previously untreated hemophilia B patients.
Synapse has enriched 10 related papers. Consider them for comparative context: